COMMUNIQUÉS West-GlobeNewswire

Ossur Hf : Trading of Össur shares to be concentrated on Nasdaq Copenhagen from 6 December 2017

30/10/2017 - 08:37

Announcement no. 77/2017 30 October 2017 Trading of Össu r shares to be concentrated on Nasdaq Copenhagen from 6 December 2017 Trading of Össur shares will soon be concentrated on Nasdaq Copenhagen following Nasdaq [...]

MITHRA COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US & CANADA

30/10/2017 - 07:30

PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR estelle® phase iii study in US & Canada Estelle ® Phase III study in US/Canada remains on track to report top line data in Q1 2019 Study recruited 2148 women in total; [...]

ESPERITE (ESP) : L1 Capital subscribes to the Ninth tranche of investment today

30/10/2017 - 07:17

Amsterdam, The Netherlands - 30 October 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Ninth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA

30/10/2017 - 07:15

Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a major concern for AS and [...]

Glycotope: Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

30/10/2017 - 07:05

Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany - (October 30, 2017) - Daiichi Sankyo Company [...]

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

30/10/2017 - 07:00

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 30, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that the company has entered into an agency [...]

MDxHealth a conclu un contrat de distribution avec Unilabs pour le test de détection du cancer de la prostate SelectMDx

30/10/2017 - 07:00

COMMUNIQUÉ DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 30 octobre 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé aujourd'hui que l'entreprise avait [...]

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

30/10/2017 - 07:00

Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]

CapsoVision annonce l'obtention du marquage CE pour l'utilisation de sa vidéo-capsule CapsoCam Plus chez les patients âgés de 2 ans et plus

30/10/2017 - 07:00

La technologie disruptive de CapsoCam Plus offre des images latérales panoramiques de 360º et leur enregistrement dans la capsule, éliminant ainsi le recours à des équipements externes. SARATOGA, Californie, le 25 [...]

Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio

30/10/2017 - 07:00

Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera ® , a first-in-class RadioLigand Therapy (RLT) approved in Europe and [...]

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

28/10/2017 - 08:55

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying therapies for children and [...]

ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES

27/10/2017 - 22:30

REGULATED INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]

uniQure Announces Closing of its Public Offering

27/10/2017 - 22:03

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]

UPDATE -- CapsoVision, Inc. Announces CE Mark for the Use of CapsoCam Plus Capsule Endoscopy System in Patients Ages 2 and Above*

27/10/2017 - 22:02

Award-winning technology provides 360º imaging, eliminates need for receiver equipment during examination SARATOGA, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Today Silicon Valley-based CapsoVision, Inc. announced CE [...]

NEOVACS : RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES

27/10/2017 - 17:45

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES FIN DU RECRUTEMENT DES PATIENTS DANS L'ÉTUDE CLINIQUE DE PHASE IIb AVEC l'IFNalpha [...]

NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS

27/10/2017 - 17:45

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF [...]

Shire plc : 3rd Quarter Results

27/10/2017 - 13:00

Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating cash flow; remain on- [...]

Preferred Dental Technologies Inc. ("Company") (CSE: PDT): Addresses the growing digital dentistry market

27/10/2017 - 11:30

Prototypes for EAS have been successfully created in multiple materials WINNIPEG, Manitoba, Oct. 27, 2017 (GLOBE NEWSWIRE) -- PDT's Evolutionary Accessory Series (EAS) is used to create custom dental abutments for the [...]

Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

27/10/2017 - 07:15

Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology medicine filgrastim [...]